How AMT-143 could reduce the post-surgical need for opioids
Press Release
In June 2022, we created and published “Meet AmacaThera and learn about our novel hydrogel platform,” a 35-second animation.
Watch the AMT-143 animation below:
The short video explains how AMT-143, our first formulation, addresses the critical 72-hour postoperative period when patients report the highest pain levels. When approved, it may help to reduce patients’ risk of opioid dependency while increasing relief.
About AmacaThera
AmacaThera is a clinical-stage biotechnology company developing a novel drug delivery platform to improve patient outcomes across multiple therapeutic areas, including post‑surgical pain management, cancer and other hard‑to‑reach target areas.
AmacaThera Closes Series A Extension to Advance Clinical Development of Long Acting, Localized, Non-Opioid Therapeutics to Improve Post-Surgery Patient Care
Press Release
AmacaThera, a leader in the development of novel injectable, localized therapeutics based upon its AmacaGel delivery platform, announced the closing of a CAD$4.0 million financing round.Read more
New study setting the stage for non-opioid analgesic in post-surgical pain management
Press Release
AmacaThera collaborates with University Health Network to evaluate the economic impact of post-surgical opioid use. They are developing non-opioid analgesic, AMT-143, aiming to reduce the reliance on opioid medications.Read more
AmacaThera Doses First Subjects in Phase 1 Clinical Trial for AmacaGel™ Therapeutic Platform
Press Release
AmacaThera Inc today announced that the first subjects have been dosed in the company's Phase 1 first-in-human clinical investigation of the safety of AmacaGel™.Read more